EichorEICHOR
Condition: Relapsed B Cell Non Hodgkin Lymphoma Synced from ClinicalTrials.gov · August 06, 2026

Recruiting studies: Relapsed B Cell Non Hodgkin Lymphoma

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Combining Loncastuximab Tesirine and Epcoritamab in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)
Phase 2 · 34 location(s) · Universität Münster · NCT07197307One Trial to Evaluate the Safety, Tolerability and Efficacy of JCXH-213 in Patients With r/r B-NHL
NA · 1 location(s) · Beijing GoBroad Hospital · NCT066183133'-Deoxy-3'-[18F] Fluorothymidine PET Imaging in Patients With Cancer
Phase N/A · 1 location(s) · Barbara Ann Karmanos Cancer Institute · NCT00935090Single-Arm Comprehensive Ablative Bridging Irradiation I Prior to CD19 CAR-T In High-Risk R/R LBCL
Phase 2 · 1 location(s) · H. Lee Moffitt Cancer Center and Research Institute · NCT06104592Polymer-lipid Particle-delivered CAR1920 mRNA CAR-T Therapy for Relapsed/Refractory B-cell Lymphoma/Leukemia
Phase 2 · 1 location(s) · Daihong Liu · NCT07321301Efficacy and Safety of CD19CD20-CAR.p40-T in B-cell Lymphoma
Phase 1/Phase 2 · 1 location(s) · Shenzhen University General Hospital · NCT07097207JY231(JY231) Injection for the Treatment of Relapsed or Refractory B Cell Lymphoma/ Leukemia
NA · 1 location(s) · Tongji Hospital · NCT06689917A Clinical Study Exploring CT1190B in the Treatment of Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
Phase 1 · 1 location(s) · Kai Hu · NCT06822868Clinical Study of Hospital-manufactured CD19 CAR-T in Children and Adolescents With Acute Lymphoblastic Leukemia
Phase 1 · 1 location(s) · Seoul National University Hospital · NCT05210907CAR T Cells in the Treatment of Refractory and Relapsed CD19+ B Cell Neoplasms
Phase 1 · 2 location(s) · FamiCordTx · NCT06593145Study to Evaluate the Efficacy of Axicabtagene Ciloleucel in Patients With Late Relapse of Diffuse Large B-Cell Lymphoma
Phase 2 · 15 location(s) · Grupo Español de Linfomas y Transplante Autólogo de Médula Ó · NCT07254754Testing the Effect of Teclistamab on Recurrent Plasmablastic Lymphoma
Phase 1 · 2 location(s) · National Cancer Institute (NCI) · NCT07332507A Multicenter Observational Study to Understand the Clinical Characteristics, Treatment Patterns and Access to Novel The
Phase N/A · 21 location(s) · AstraZeneca · NCT07065344Efficacy and Safety Evaluation of U01(ssCART-19) in B-Cell Lymphoma
Phase 1/Phase 2 · 1 location(s) · Shanghai Tongji Hospital, Tongji University School of Medici · NCT06987916LV20.19 CAR T-Cells in Combination With Pirtobrutinib for Relapsed, Refractory B-cell Malignancies
Phase 1 · 1 location(s) · Medical College of Wisconsin · NCT05990465Clinical Study of C402-CD19-CAR Treatment in Subjects With Relapsed or Refractory B-cell Lymphoma
Phase 1 · 1 location(s) · Shanghai Exuma Biotechnology Ltd. · NCT06830031Anti-CD30 biAb-AATC in Patients With Relapsed/Refractory CD30 Positive Hematopoietic Malignancies
Phase 1 · 1 location(s) · Medical College of Wisconsin · NCT05544968Pembro Plus CAR T-cell Therapy in R/R in PMBCL
Phase 2 · 2 location(s) · Jennifer Crombie, MD · NCT05934448Registry of Older Patients With Cancer
Phase N/A · 7 location(s) · UNC Lineberger Comprehensive Cancer Center · NCT01137825A Study of Ultra-fraction Radiotherapy Bridging CART in R/R DLBCL
NA · 1 location(s) · Peking Union Medical College Hospital · NCT05514327TCR Reserved and Power3 (SPPL3) Gene Knock-out Allogeneic CD19-targeting CAR-T Cell Therapy in r/r B Cell Lymphoma
Phase 1/Phase 2 · 3 location(s) · Chinese PLA General Hospital · NCT06323525Real World Practice With Academic Anti CD19 CAR-T Cell Therapy in Relapse/Refractory B-cell Lymphoma
Phase N/A · 1 location(s) · N.N. Alexandrov National Cancer Centre · NCT07524816A Phase 1/2 Study of STP938 (Dencatistat) for Adult Subjects With Relapsed/Refractory B-Cell and T-Cell Lymphomas
Phase 1/Phase 2 · 15 location(s) · Step Pharma, SAS · NCT05463263Safety and Efficacy of CAR T Cell Therapy in Patients with R/r B-ALL
Phase 1/Phase 2 · 1 location(s) · Kara Yakhteh Tajhiz Azma Company · NCT06635330A Study of CD19 Targeted CAR T Cell Therapy in Pediatric Patients With Relapsed or Refractory B Cell Acute Lymphoblastic
Phase 1 · 8 location(s) · Autolus Limited · NCT06173518Clinical Study of U01（ssCART-19） in Patients With B-Cell Lymphoma
Phase 1 · 1 location(s) · Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd · NCT07093073A Study of Automated Axicabtagene Ciloleucel for R/R Large B-cell Lymphoma.
EARLY_Phase 1 · 6 location(s) · Shenzhen Fosun Kairos Biotechnology Co., Ltd. · NCT07606937Clinical Study of Cord Blood-derived CAR-NK Cells Targeting CD19 in the Treatment of Refractory/Relapsed B-cell NHL
Phase 1 · 1 location(s) · Second Affiliated Hospital, Zhejiang University, School of M · NCT05472558Study Adding Drugs to Usual Treatment for Large B-Cell Lymphoma That Returned or Did Not Respond to Treatment
Phase 2 · 104 location(s) · SWOG Cancer Research Network · NCT05890352CNS-Relapse Prevention in High-Risk Diffuse Large B-cell Lymphoma With Thiotepa-based Autologous Stem Cell Transplant
Phase 2 · 1 location(s) · Washington University School of Medicine · NCT06687772
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →
Eichor
Clinical intelligence from public evidence
Use of Eichor is governed by our Terms of Use · Privacy Policy
© 2026 Biomedistats LLC (dba Eichor)

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.